PBRM1 mutation

#FeatureFriday Today on #FeatureFriday, we are featuring a tweet by Dr. Milind Javle [@JavleMilind] about how the PBRM1 mutated biliary tract cancer subtypes aid in predicting sensitivity to PARP inhibitors. #MedTwitter (@4baseCare)

Now online in @Nature_NPJ: "PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system." From the team of Dr. Andreas Seeber @imed_tweets and @carisls GI Onc Precision Oncology Alliance collaboration. (@cancerassassin1)

Sharing collaborative study by Dr. Andreas Seeber and @carisls👇 PBRM1 mutations might render a subtype of biliary tract cancers sensitive to drugs targeting the DNA damage repair system https://t.co/cg5o8yOwf6 (@weldeiry)

🔘 Exploration of Morphological Features of Clear Cell Renal Cell Carcinoma With PBRM1, SETD2, BAP1, or KDM5C Mutations #kidneycancer @IJSPjournal https://t.co/BfSG2ZNQU8 (@drenriquegrande)

@CIR_AACR #OnlineFirst: #PBRM1 plays a novel role in #ccRCC. The data may explain the clinical association of PBRM1-mutant ccRCC with positive prognosis & improved #ICB responses. @WilliamKimMD @jeremy_m_simon @ahepperla @UNC_Lineberger @UNCurology (@Adri_CIR)

1/ Ever wonder why PBRM1 mutations are associated with #ICB response specifically in kidney cancer??? Our recent paper offers a potential explanation! https://t.co/NPcH5ww1aw (@WilliamKimMD)

2/ #ccRCC is an immunotherapy responsive disease but reasons underlying this are not fully clear. Studies have variably implicated PBRM1 mutations as a predictive biomarker of ICB response. Key work from @vanallenlab @BraunMDPhD @diana_miao @DrChoueiri @motzermd Dave McDermott (@WilliamKimMD)

3/ Intriguingly, PBRM1 mutations have primarily been associated with ICB response in ccRCC, but not other tumor types. @sarahaboualaiwi @DrChoueiri https://t.co/q9HJ93Xr3g (@WilliamKimMD)

8/ From my post-doctoral work in the @kaelin_lab I knew that #VHL mutations are specific to ccRCC. We hypothesized PBRM1’s specificity as a predictive biomarker of ICB response was d/t interaction with VHL inactivation and HIF upregulation. (@WilliamKimMD)

@CIR_AACR #OnlineFirst: #PBRM1 plays a novel role in #ccRCC. The data may explain the clinical association of PBRM1-mutant ccRCC with positive prognosis & improved #ICB responses. @jeremy_m_simon @WilliamKimMD @katehacker_uro @ahepperla @UNC_Lineberger @UNCurology 🧵🧵👇👇👇 (@Adri_CIR)

Great work! Given your findings of pbrm1 co-localization with setd2 methyl mark, curious your thoughts on the frequent co-mutation seen in humans ccrcc Between Pbrm1 and setd2 (@arihakimi)

A new study on PBRM1 mutations and RCC from @VanAllenLab @DrChoueiri here: https://t.co/KBkiQXkPHO My two cents which are worth less than two cents (w/disclosure that I am a middle author on the MSK study led by the brilliant @arihakimi) on the real value of this: (@EdReznik)

While patients with PBRM1-mutated clear cell RCC tumors have better prognosis, they may have decreased response to checkpoint inhibitors. Great work Xian-De, Eric, and others! @KimrynRathmell @katy_beckermann https://t.co/uYYLJKsJCi (@DrScottHaake)